Salmen, T.; Potcovaru, C.-G.; Bica, I.-C.; Giglio, R.V.; Patti, A.M.; Stoica, R.-A.; Ciaccio, M.; El-Tanani, M.; Janež, A.; Rizzo, M.;
et al. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. Pharmaceuticals 2024, 17, 1322.
https://doi.org/10.3390/ph17101322
AMA Style
Salmen T, Potcovaru C-G, Bica I-C, Giglio RV, Patti AM, Stoica R-A, Ciaccio M, El-Tanani M, Janež A, Rizzo M,
et al. Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. Pharmaceuticals. 2024; 17(10):1322.
https://doi.org/10.3390/ph17101322
Chicago/Turabian Style
Salmen, Teodor, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana-Adriana Stoica, Marcello Ciaccio, Mohamed El-Tanani, Andrej Janež, Manfredi Rizzo,
and et al. 2024. "Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review" Pharmaceuticals 17, no. 10: 1322.
https://doi.org/10.3390/ph17101322
APA Style
Salmen, T., Potcovaru, C. -G., Bica, I. -C., Giglio, R. V., Patti, A. M., Stoica, R. -A., Ciaccio, M., El-Tanani, M., Janež, A., Rizzo, M., Gherghiceanu, F., & Stoian, A. P.
(2024). Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. Pharmaceuticals, 17(10), 1322.
https://doi.org/10.3390/ph17101322